

REMARKS

Reconsideration and allowance are respectfully requested. Claims 1-8 and 10-14 are pending. The amendments are fully supported by the original disclosure and, thus, no new matter is added by their entry. They reduce the issues on appeal.

The Examiner objected to the sequence listing. In response thereto, Applicants correct the sequence listing, and submit herewith paper and computer readable copies thereof. They do not add new matter, and their contents are the same.

Claims 1-8 and 10-14 were rejected under Section 112, second paragraph, as being allegedly indefinite. Applicants traverse because the present amendments moot the objections. The Examiner's suggestions for amending the claims to correct informalities are gratefully acknowledged. Markush groups are properly formatted. The definition of $-NX_4-R_4-$ is deleted because the limitation is not required for patentability. As regards the proviso, the definition of α -fluoroalkylated amino acid is found on pages 4-5 of the specification. Thus, the α -fluoroalkyl is attached to the $C\alpha$ of the amino acid. By contrast, the difluoromethyl (Dfm) and trifluoromethyl (Tfm) act as protecting groups to block the nitrogen of the amino acid, which is described on page 8 of the specification. Applicants request withdrawal of the rejection because the pending claims are definite.

Claims 1, 3-8 and 10-14 were objected to as allegedly informal. Adoption of the Examiner's suggestion moots this objection. Applicants request its withdrawal.

Having fully responded to the pending Office Action, Applicants submit that the claims are in condition for allowance and earnestly solicit an early Notice to that effect. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /Gary R. Tanigawa/

Gary R. Tanigawa
Reg. No. 43,180

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100